TMS Therapy for Depression, OCD & Dual Diagnosis
A Non-Invasive, FDA-Approved Option for Treatment-Resistant Depression
Transcranial Magnetic Stimulation (TMS) uses a focal electromagnetic coil positioned against the scalp to modulate cortical activity in the mood-regulation network. It has been FDA-approved for treatment-resistant major depression since 2008 and is now covered by Medicare and virtually every commercial insurance plan when clinical criteria are met.
Why TMS matters in a dual-diagnosis program
Depression and addiction share overlapping neurocircuitry — the prefrontal cortex, anterior cingulate, and limbic system are dysregulated in both conditions. TMS acts precisely on this circuitry, and randomized trials increasingly show benefit not just for depression but for the craving component of alcohol, cocaine, and nicotine use disorders. This makes TMS uniquely valuable in a program built around dual-diagnosis care.
At RECO Health, TMS is offered as part of the mental-health specialty stack alongside IV ketamine, medication management, and evidence-based psychotherapy — so patients get the intervention that fits their clinical picture, not a one-size-fits-all protocol.
What sets TMS apart from medications and ECT
TMS is non-systemic — the electromagnetic field acts only on the tissue directly under the coil (about 2-3 cm deep), so there are no sexual, weight, GI, or cognitive side effects. It requires no sedation, so you drive yourself to every session and return to work the same day. And unlike ECT, it produces no memory impairment. The trade-off is that TMS is time-intensive: 36 sessions over 6-9 weeks for a standard course, though the iTBS protocol compresses each session to just 3 minutes.
The Neuroscience of Transcranial Magnetic Stimulation
TMS uses Faraday's principle of electromagnetic induction to generate a rapidly changing magnetic field via a coil placed against the scalp. That field passes non-invasively through the skull and induces a small electrical current in the underlying cortical neurons, depolarizing them and either enhancing or suppressing activity in that region depending on the stimulation frequency.
For depression treatment, the coil is positioned over the left dorsolateral prefrontal cortex (DLPFC) — a region that meta-analyses consistently show to be hypoactive in major depressive disorder. High-frequency (10 Hz) stimulation over the left DLPFC restores normal activity in this region and, through its downstream connections, in the broader mood-regulation network that includes the anterior cingulate, subgenual cingulate, and limbic system.
- Motor threshold determination: Before treatment, the intensity is calibrated to your individual motor threshold — the minimum output required to elicit a small thumb twitch when the coil is placed over the motor cortex. Treatment intensity is typically 120% of this threshold.
- Coil positioning: The coil is placed 5-6 cm anterior to the motor threshold hotspot, targeting the left DLPFC. Neuronavigation using an MRI is available for cases where standard positioning has not produced response.
- Stimulation: Standard rTMS delivers 3,000 pulses at 10 Hz in trains of 4 seconds on / 26 seconds off across a 37-minute session. iTBS delivers 600 pulses in short bursts across a 3-minute session with equivalent efficacy.
- Cumulative plasticity: A single session produces transient changes, but repeated sessions over 6-9 weeks produce lasting normalization of prefrontal circuit activity and clinical response.
FDA-Approved and Evidence-Supported Indications
Treatment-Resistant Depression (FDA-approved)
The core FDA indication since 2008. Standard clinical criterion is failure or intolerance of at least two adequate antidepressant trials, plus a documented course of psychotherapy. Standard 36-session rTMS or 30-session iTBS course. Response rate around 55%, remission rate around 35% in well-designed trials.
Obsessive-Compulsive Disorder (FDA-approved 2018)
Deep TMS with an H-coil targeting bilateral medial prefrontal cortex and anterior cingulate. Standard course is 29 sessions. FDA-approved as adjunct to ongoing exposure-and-response-prevention therapy and SSRI treatment, not as monotherapy.
Smoking Cessation (FDA-approved 2020)
Deep TMS targeting bilateral lateral prefrontal cortex and insula, using a specific H4 coil. Standard course is 18 sessions across 6 weeks. Reduces nicotine craving and increases quit rates as demonstrated in the pivotal registration RCT.
PTSD (Off-Label, Growing Evidence)
Multiple RCTs support rTMS targeting right DLPFC or medial prefrontal cortex as adjunct to trauma-focused psychotherapy (prolonged exposure, CPT). Particularly relevant for patients with treatment-refractory PTSD or those unable to tolerate exposure work early in treatment.
Alcohol and Cocaine Use Disorder (Off-Label, Emerging)
Randomized trials in alcohol use disorder show significant reductions in craving and heavy-drinking days with high-frequency TMS to the left DLPFC. Similar RCT evidence in cocaine use disorder. Offered as an adjunct to structured addiction therapy in our dual-diagnosis program.
Bipolar Depression (Off-Label, Selected Cases)
For bipolar II or well-controlled bipolar I patients in a depressive episode refractory to mood-stabilizer optimization, rTMS may be considered with concurrent mood stabilizer coverage. Not appropriate for active mania or mixed states.
Your Standard 36-Session TMS Course, Step by Step
Psychiatric consultation and insurance authorization
A 60-minute intake with our psychiatric provider documents your medication history, prior antidepressant trials, current symptoms with baseline PHQ-9/MADRS/GAD-7 scoring, medical history (particularly seizure risk factors and metal implants), and treatment goals. Our billing team then submits the prior-authorization to your insurance carrier; approval typically comes within 5-7 business days.
Motor threshold determination (session 1)
The first appointment includes calibration of your individual motor threshold. The coil is placed over the motor cortex, and stimulation intensity is gradually increased until a small thumb twitch is reliably elicited. This threshold is unique to each patient and determines your treatment intensity, which will be set at approximately 120% of that value.
A typical daily session
You arrive at your scheduled appointment, remove any metal jewelry above the neck, and take a seat in the reclining treatment chair. The TMS technologist positions the coil over the left dorsolateral prefrontal cortex using the individualized landmarks. Stimulation begins — 37 minutes of gentle scalp tapping in 4-second trains for standard rTMS, or 3 minutes for iTBS. You can read, listen to music, or converse. You walk out and drive home immediately.
Response tracking and mid-course adjustment
PHQ-9 is re-scored weekly. Approximately half of responders show early response by session 10-15; the remainder respond more gradually. If minimal response is documented by session 20, we discuss adjustment options: switching from rTMS to iTBS, adding neuronavigation, or considering an alternative pathway (Spravato, IV ketamine). We do not run out the full 36 sessions on a non-responder.
Course completion and taper
Sessions 30-36 include a gradual taper of frequency (5 days/week → 3/week → weekly for the final two weeks) which appears to enhance response durability. Ongoing antidepressant medication and psychotherapy continue unchanged through the taper.
Maintenance plan and long-term follow-up
Post-course, we track PHQ-9 monthly for the first six months and quarterly thereafter. About two-thirds of responders maintain remission at 12 months with no additional treatment; the remainder are offered periodic maintenance sessions (typically 5-10 sessions across 2 weeks at the earliest sign of symptom re-emergence). This "prompt-retreatment" strategy is more effective than fixed monthly maintenance.
Safety Profile, Contraindications, and Side Effects
Contraindications we screen for
Absolute contraindications include ferromagnetic implants in or near the head (aneurysm clips, cochlear implants, cardiac pacemaker leads within 30 cm of the coil, deep brain stimulator leads) and metallic foreign bodies in the head. Relative contraindications include a personal history of seizures, active substance withdrawal (especially alcohol or benzodiazepines), significant traumatic brain injury with skull defect, and use of medications that lower seizure threshold at high doses.
Common side effects
Scalp discomfort under the coil during stimulation is the most common issue — reported by about 30% of patients early in the course and typically resolving by session 5. Mild post-session headache is second-most-common; over-the-counter acetaminophen or ibuprofen is effective. Transient hearing sensitivity from the coil clicking sound is prevented with earplugs supplied at every session.
Rare serious events
The most serious risk is TMS-induced seizure, which occurs at a rate of less than 1 per 30,000 sessions with FDA-approved protocols and appropriate screening. Our clinical staff are trained in seizure response, and every treatment room is equipped with emergency equipment. No cognitive impairment, no memory loss, no personality change has been documented from FDA-approved TMS protocols.
Interactions we monitor
Medications that lower seizure threshold (bupropion at high doses, tramadol, some antipsychotics) are reviewed with your prescriber before starting TMS; often the dose or medication can be adjusted safely without discontinuing. Benzodiazepines and anticonvulsants can blunt TMS response and are discussed on a case-by-case basis. Nicotine, caffeine, and alcohol use is documented at each visit.
Insurance Coverage for TMS Therapy
TMS is covered by Medicare and by virtually every major commercial insurance plan — Aetna, Cigna, UnitedHealthcare, Humana, Florida Blue, and others — when documented clinical criteria for treatment-resistant depression are met. Standard prior-authorization requires:
- Documented failure or intolerance to at least two adequate antidepressant trials from different classes at therapeutic dose and duration.
- A prior or concurrent course of psychotherapy of adequate duration.
- Absence of a psychotic disorder or active bipolar mania.
- No contraindication to TMS (metal implants, uncontrolled seizure disorder).
Our billing team completes the prior-authorization submission on your behalf and typically obtains approval within 5-7 business days. Copays and deductibles vary by plan; we review the exact out-of-pocket estimate before you commit to the course.
Frequently Asked Questions
Transcranial Magnetic Stimulation (TMS) uses a focal electromagnetic coil placed against the scalp to induce electrical currents in the underlying cortical neurons. For depression, the coil is positioned over the left dorsolateral prefrontal cortex, a region that is consistently hypoactive in major depressive disorder. Repeated stimulation over 6-9 weeks appears to restore normal activity in the mood-regulation network, with FDA approval for treatment-resistant depression since 2008 and expanded indications for OCD (2018) and smoking cessation (2020).
TMS is not painful in the medical sense, though most patients describe a firm tapping or knocking sensation on the scalp under the coil that can be uncomfortable during the first few sessions. Scalp desensitization is common — by session five most patients report the sensation as easily tolerable. You remain fully awake, alert, and conversational throughout the session; no sedation is required, and you can drive yourself to and from every appointment.
TMS produces response rates comparable to antidepressant medications for major depression but is specifically indicated for treatment-resistant cases where medications have failed. Unlike SSRIs, TMS does not cause sexual side effects, weight gain, sedation, or GI symptoms. Unlike ECT, TMS does not require anesthesia, does not cause memory impairment, and does not require inpatient care. ECT remains the most effective single treatment for severe or catatonic depression, but TMS is the appropriate first choice for outpatient treatment-resistant depression.
The standard rTMS course is 36 sessions delivered five days per week over six to nine weeks. Each rTMS session runs about 37 minutes of actual stimulation, plus 5-10 minutes of setup, so plan for about 45 minutes in-office per visit. iTBS (intermittent theta burst stimulation) achieves comparable response in 3-minute stimulation sessions and is preferred for patients who need to fit treatment around a work schedule. Maintenance sessions after a full course are individualized based on response durability.
Yes. TMS is FDA-approved and covered by Medicare and virtually all major commercial insurance plans — Aetna, Cigna, UnitedHealthcare, Humana, Florida Blue, and others — when clinical criteria for treatment-resistant depression are met. Standard prior-authorization requires documentation of failure or intolerance to at least two adequate antidepressant trials and a formal course of psychotherapy. Our billing team handles the prior-authorization process and typically completes it within 5-7 business days of the initial consult.
The most common side effects are scalp discomfort under the coil during stimulation (usually resolves after the first week) and mild post-session headache (responds to over-the-counter analgesics). Transient hearing sensitivity is prevented with earplugs. The most serious risk is TMS-induced seizure, which is very rare (<1 in 30,000 sessions with FDA-approved protocols) and requires careful screening for prior seizures, active alcohol withdrawal, and QT-prolonging medications. TMS does not cause the sexual, cognitive, weight, or GI side effects that limit antidepressant medication use.
Yes, and this is standard clinical practice. TMS is nearly always delivered as augmentation to an ongoing antidepressant regimen rather than as monotherapy. There is no requirement to stop your current medications before starting TMS; in fact, discontinuing an antidepressant to start TMS is not recommended because it can worsen depression during the induction phase. Our psychiatric team coordinates directly with your outpatient prescriber so medication management stays continuous through the TMS course.
Response durability varies significantly across patients. For those who achieve full remission after 36 sessions, published follow-up data suggest that about two-thirds maintain response at 12 months with no additional treatment, while the remainder benefit from periodic maintenance sessions or booster courses. Predictors of durable response include earlier onset of response during the acute course, concurrent psychotherapy, and a stable maintenance antidepressant regimen. Our team follows every patient with PHQ-9 monitoring for at least 12 months post-course and offers maintenance TMS when clinically indicated.
Evidence Base and References
- O'Reardon JP, Solvason HB, Janicak PG, et al. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry. 2007;62(11):1208-1216. PubMed 17573044.
- Blumberger DM, Vila-Rodriguez F, Thorpe KE, et al. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. Lancet. 2018;391(10131):1683-1692. PubMed 29726344.
- Perera T, George MS, Grammer G, et al. The Clinical TMS Society Consensus Review and Treatment Recommendations for TMS Therapy for Major Depressive Disorder. Brain Stimul. 2016;9(3):336-346. PubMed 27090022.
- Carmi L, Tendler A, Bystritsky A, et al. Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective Multicenter Randomized Double-Blind Placebo-Controlled Trial. Am J Psychiatry. 2019;176(11):931-938. PubMed 31109199.
- Zangen A, Moshe H, Martinez D, et al. Repetitive transcranial magnetic stimulation for smoking cessation: a pivotal multicenter double-blind randomized controlled trial. World Psychiatry. 2021;20(3):397-404. PubMed 34505365.
- Mishra BR, Nizamie SH, Das B, Praharaj SK. Efficacy of repetitive transcranial magnetic stimulation in alcohol dependence: a sham-controlled study. Addiction. 2010;105(1):49-55.